Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Authors Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al

Published Date November 2010 Volume 2010:6 Pages 1023—1037

DOI http://dx.doi.org/10.2147/VHRM.S13496

Published 10 November 2010

Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse2
1Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, Australia

Abstract: High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin–ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

Keywords: familial hypercholesterolemia, ezetimibe, statin, combination therapy, low-density lipoprotein cholesterol

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Lipid-modifying therapy in the elderly

Hamilton-Craig I, Colquhoun D, Kostner K, Woodhouse S, d'Emden M

Vascular Health and Risk Management 2015, 11:251-263

Published Date: 14 May 2015

Readers of this article also read:

Serum lipid profile and correlates in newly presenting Nigerians with arterial hypertension

Adamu UG, Okuku GA, Oladele CO, Abdullahi A, Oduh JI, Fasae AJ

Vascular Health and Risk Management 2013, 9:763-768

Published Date: 3 December 2013

Management of pediatric corneal limbal dermoids

Pirouzian A

Clinical Ophthalmology 2013, 7:607-614

Published Date: 28 March 2013

Critical appraisal of ticagrelor in the management of acute coronary syndrome

Nawarskas JJ, Snowden SS

Therapeutics and Clinical Risk Management 2011, 7:473-488

Published Date: 5 December 2011

Nonselective ß-blocker propranolol for orbital and periorbital hemangiomas in infants: a new first-line of treatment?

El-Essawy R, Galal R, Abdelbaki S

Clinical Ophthalmology 2011, 5:1639-1644

Published Date: 18 November 2011

Filament formation associated with spirochetal infection: a comparative approach to Morgellons disease

Middelveen MJ, Stricker RB

Clinical, Cosmetic and Investigational Dermatology 2011, 4:167-177

Published Date: 14 November 2011

Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles

Dongmei Zhao, Xiuhua Zhao, Yuangang Zu, et al

International Journal of Nanomedicine 2010, 5:669-677

Published Date: 13 September 2010

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010